Crucially, the extract exhibited potent dual cholinesterase inhibition, with an IC50 of 4.87 μg/mL (AChE) and 40.99 μg/mL (BChE), suggesting its ability to enhance cholinergic neurotransmission—a key therapeutic target in AD. The gene discussed is ACHE; the disease is Alzheimer disease.